Recently initiated clinical trials are investigating potential treatments for CH/CCUS, including anti–IL-1β antibody canakinumab for high-risk CCUS (to attenuate inflammation-driven clonal expansion) (159) (NCT05641831), the administration of vitamin C (a cofactor of TET2) for TET2-CCUS (NCT03418038), and the exploration of targeted therapies such as IDH1/2 inhibitors in IDH1/2-CCUS (NCT05030441 and NCT05102370). Here, IDH1 is linked to cyclic hematopoiesis.